Live Webinar SaaS Valuations in 2026: Public and Private Markets Update Tue, Nov 17 11am ET / 5pm CET Register

Tentamus Acquisitions: What It Buys and What Labs Sell For

For owners of food, pharmaceutical, medical device and other testing laboratories weighing a sale to Tentamus or one of its companies.

Marcin Majewski
Published November 15, 2026 · 12 min read · Connect on LinkedIn

Tentamus Group, a Berlin owner of testing laboratories backed by the private equity firm BC Partners, has made 66 acquisitions since 2015 by our count, mostly food and agricultural testing labs or pharmaceutical and medical device testing labs. For the owner of such a lab, the best guide to its value is what small TIC (testing, inspection and certification) firms sell for, because neither Tentamus nor any seller or advisor has published a price for any of the 66. In our research, TIC deals under $50M sold at a median 8.0x EBITDA (21 deals).

Tentamus Group Companies and Labs

Jochen Zoller and Abgar Barseyten founded Tentamus in 2011. Auctus Capital Partners, a Munich private equity firm, backed it from its founding. BC Partners invested in 2021 and lists Tentamus as a current investment, without saying how large a stake it holds.

Christian Rebhan has been chief executive since April 2024. At the same time Zoller became chairman and Barseyten a board member, and Tentamus said the two founders “will focus on mergers and acquisitions” (release, 2 April 2024).

An approach can come from a Tentamus company as well as from the group. Seven of the 66 acquisitions were made by its companies, three of them by Veltia, which runs Tentamus’s labs in Greece, Cyprus, Bulgaria and Turkey and is built on the 70% of the Greek lab Agrolab RDS that Tentamus bought in 2019. Companies such as VelaLabs in Austria and BAV Institut in Germany made the rest. Outside Germany, Tentamus runs country groups under its own name in Iberia, Italy, North America and the UK.

By its own figures, Tentamus has “more than 90 locations in over 23 countries” and 3,200 employees (tentamus.com, November 2026). It does not state its revenue. Its group accounts to 2020 are filed in the German company register, and we found none for later years.

How Many Companies Tentamus Acquires, and What Size

Tentamus bought about seven companies a year from 2015 to 2021, with 15 in 2021 alone. Since 2022 it has bought about three a year.

Tentamus acquisitions per year66 acquisitions since 2015; 2026 is January to 14 November048121642015720164201782018102019220201520216202232023520240202522026**January to 14 November.
Source: Aventis Advisors TIC deal database.

Eleven of the 66 deals have a published headcount. Eight of those labs had 50 staff or fewer, the smallest 10, and the other three had 100 to 150. Only one source states a lab’s revenue, so headcount is the best guide to size. Labs of that size compare with the smallest band in our valuation research, deals under $50M.

What Tentamus Buys and Where

Food and agricultural labs, counting those that test supplements and cosmetics, make up 40 of the 66 acquisitions, and pharmaceutical and medical device labs 19.

Type of lab Acquisitions
Food, feed and beverage testing labs, including sensory, wine and olive oil labs 30
Agricultural and agrochemical testing labs, including crop protection studies and plant and seed labs 4
Supplement, cosmetics and related testing labs 6
Pharmaceutical and biotech testing labs 13
Medical device testing, including biocide efficacy and device consultancies 6
Environmental, water and packaging testing labs 3
Regulatory and quality consulting 4
Source: Aventis Advisors TIC deal database.

Forty-seven of the 66 deals were in Europe, not counting Turkey, 11 of them in Germany. Outside Europe, the United States leads with 10.

Where Tentamus buys66 acquisitions since 2015, by country of the lab boughtGermany11United States10Italy9Spain8United Kingdom8France5Greece3Austria2Israel2China (incl. a lab in Taiwan)1Seven other countries, 1 each7
Source: Aventis Advisors TIC deal database. Seven other countries: Canada, India, Japan, Mexico, Portugal, Turkey and Vietnam.

Since 2022 it has bought where it already had labs. Fifteen of its 16 purchases from 2022 on were in countries where it had bought before, and the one new country was Vietnam, in 2023.

What Labs Like These Sell For: Acquisition Multiples

Buyers price a lab as a multiple of its EBITDA (earnings before interest, tax, depreciation and amortization), adjusted for one-off costs and the owner’s own pay. At 8x, a lab with $1.5M of EBITDA is worth $12M. That is its enterprise value, the value of the whole business, from which the owner repays any debt and keeps the rest.

The labs whose size is known are small, so the fair comparison in our TIC valuation research is TIC deals under $50M, which sold at a median 8.0x EBITDA (21 deals) and 1.52x revenue (80 deals). Our research holds only eight lab deals under $50M with a published EBITDA multiple, too few for a separate figure, so the TIC band is the guide.

Set Median EBITDA multiple Deal sizes in the set
TIC deals under $50M 8.0x (21 deals) Under $50M
Testing laboratory deals 10.1x (24 deals) Every size, median about $60M
Food and agricultural testing labs 10.8x (5 deals) Every size
Pharmaceutical and medical device testing labs 9.2x (6 deals) Every size
All TIC deals 9.9x (54 deals) Every size
Source: Aventis Advisors TIC valuation research.

The 10.1x for testing laboratories rests on larger deals. The lab deals with a published EBITDA multiple had a median size of about $60M, against $13.4M for all lab deals with a disclosed size (128 deals). Larger deals sell for more, and across TIC, deals of $500M and over sold at a median 12.2x (11 deals). For a lab under $50M, the 8.0x is the closer guide. Our valuation pages for food and agricultural testing labs and pharmaceutical and medical device testing labs give the figures for each type of lab.

The two medians agree for a lab with an EBITDA margin near 19%. At a 15% margin, 8.0x EBITDA is about 1.2x revenue, so a lab should work from EBITDA, as buyers do. Where a lab lands depends on its size, the breadth of its accreditation and how many buyers compete for it.

What is your lab worth?

Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your lab measures up against 2,841 TIC deals, which buyer groups have acquired firms like yours, and how any offer you hold compares with what they paid where terms are published.

Request your valuation assessment or email the numbers to marcin.majewski@aventis-advisors.com.

How Tentamus Structures a Deal

In four of the six deals where the stake is known, Tentamus bought a majority, 60% to 70% where the figure is published, and the sellers kept the rest. In the other two it bought all the shares.

In one of them, an Indian lab bought in 2019, IMAP, the seller’s advisor, reported that put and call options on the founders’ 40% can be exercised after four years (IMAP deal page, November 2026). A put lets the seller require the buyer to take the shares, and a call lets the buyer require the seller to sell them.

No Tentamus announcement or advisor note that we found mentions an earn-out or a deferred payment. For an owner offered a majority, how and when the kept shares are bought matters as much as the price at closing, and in a competitive process it is one of the terms buyers bid on.

What Happens After Closing

Tentamus describes itself as a “House of Brands” in which “each company retains its specialist expertise, local relationships and individual identity” (tentamus.com, About page, November 2026). At least 13 labs kept their own name, adding the line “A Tentamus Company”. Others took a Tentamus name, such as TentaMedix in Germany and Tentamus Pharma UK.

Five of the roughly 14 announcements we could read, from 2018 to 2026, say the founder, the manager or the team stays on. We found no lab Tentamus bought and later sold or closed.

A lab may keep its name and team and still be merged into a sister lab later. Tentamus has merged companies it bought in the same country four times in Germany between 2019 and 2023, one of them the 2021 combination of three labs into one pharmaceutical and medical device company, and twice in Italy, in 2025 and 2026. The 2026 Italian merger joined two consultancies and kept both sites open.

Tentamus Competitors: Who Else Buys Testing Labs

Five other groups have each made at least 20 deals since 2015 across the two fields where Tentamus buys, food, agriculture and consumer product testing on one side and life sciences testing on the other.

Buyer Owner TIC acquisitions since 2015 Food, agriculture and consumer product testing Pharma, medical device and other life sciences
Eurofins Scientific Listed 233 99 25
SGS Listed 105 22 6
Normec Private equity (Astorg) 59 15 11
ALS Listed 37 15 6
Mérieux NutriSciences Family-controlled (Institut Mérieux) 27 21 0
Source: Aventis Advisors TIC deal database. Buyers with their own profile on our site are shown at that profile’s count.

All five have made 15 or more deals on the food and consumer side, so each is a possible buyer for a food lab. Mérieux NutriSciences has made none in life sciences, which leaves Eurofins, Normec, SGS and ALS for a pharmaceutical or medical device lab. Counted the same way, Tentamus has made more deals than any of them except Eurofins in both fields.

Is This a Good Time to Sell to Tentamus?

Tentamus still buys, but less than it did. It made 16 acquisitions from 2022 to 14 November 2026, against 50 in the seven years before. Since the founders moved to acquisitions in April 2024, it has made three more deals that year, none in 2025 and two in 2026, in our count. Four of the 16 were regulatory consultancies. Of the other 12, two were medical device or biomedical labs and two were general food labs, and the remaining eight added specialties such as sensory research, wine and olive oil analysis, seed testing, packaging testing and biomechanics. For an owner of a general food lab, the competing groups count as much as Tentamus.

Tentamus has made 66 acquisitions since 2015. An owner who answers its approach alone sells at its price and on its terms. We run a competitive process among the laboratory groups, private equity platforms and other buyers with a real reason to want your lab, so you choose between the best offers and get the best price. If keeping the lab is the better choice for you, we say so. Talk to us in confidence before you reply to Tentamus or one of its companies. Our M&A advisory for TIC companies page sets out how we work.

Before you reply to a buyer

Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your lab measures up against 2,841 TIC deals, which buyer groups have acquired firms like yours, and how any offer you hold compares with what they paid where terms are published.

Request your valuation assessment

About Aventis Advisors

We advise owners on sales with typical enterprise values between $5M and $100M, as partners of the Globalscope network. We also advise serial acquirers, which is how we know the way their offers are built and where they leave room.

Recent transactions:

  • Advice to Apave on its acquisitions of ISOCERT and De Duurzame Adviseurs.
  • Sale of CKSource, the rich-text editor developer, to PSG via Tiugo Technologies, after a global process that drew several letters of intent.
  • Advice to Visma on its acquisition of SaldeoSMART.

“We were impressed with Marcin’s negotiating skills and Aventis’ ability to make things happen.”

Sindre Talleraas Holen, M&A Director, Visma

“Aventis Advisors did the heavy lifting so that our management team could stay focused on our business.”

Wiktor Walc, President, CKSource

Write to us at marcin.majewski@aventis-advisors.com. The first conversation is confidential.

Methodology

The count covers acquisitions of testing laboratories and other TIC firms by Tentamus Group or a Tentamus company, announced from 2015 to 14 November 2026, each checked against Tentamus’s announcement or, where we found none, the seller’s or advisor’s note, the trade press or Tentamus’s own list of group members. Ten deals rest on one such source, and the years of 13 come from that list or from release numbering. Two deals, EpiLogic (no dated announcement, placed in 2021) and Lambda Cientifica (Mexico, 2021, stake not stated), count because Tentamus lists both as group companies. Three deals seen in Tentamus releases but absent from our database are not counted. The deals come from our TIC deal database, built from Mergermarket and public sources such as acquirer announcements, press releases, news and annual reports.

The group’s size, policy and management come from tentamus.com and its releases, with locations and staff as Tentamus states them. Its ownership comes from BC Partners’ website and the German company register, which shows the company at the top of the group set up in 2011 as a holding company of Auctus Capital Partners. What we say about stakes, names and managers rests on the roughly 14 deal announcements and advisor notes we could read in full or in summary, and headcounts on the 11 that state one. Stakes come from releases, advisors, law firms and other reports. Of the Tentamus releases we could read, two state the stake, and Mergermarket records 100% for one more deal, a UK lab in 2021, which no release confirms. The older releases we could not read mean these counts are floors.

Each deal is counted under the group that made it at the time. Deals made by a Tentamus company count as Tentamus deals, and deals before 2015, including the group’s first labs from 2011 to 2014, sit outside the count. Each deal counts once under the country of the lab bought, so the 2017 deal for food labs in China and Taiwan sits under China. Our TIC valuation pages credit each deal to its buyer’s owner today and still count some deals this check removed, so they show 69 for Tentamus. Our food testing laboratory page shows 40 food and agricultural deals for Tentamus because its segment takes in supplement and cosmetics labs, which have their own row here. The 66 include four regulatory and quality consulting firms that our TIC rules count as compliance work. Without them the count is 62.

The table of competitors counts each buyer’s TIC deals since 2015 under its owner today, or at its profile’s count where it has one, and lists every group with 20 or more deals in food, agriculture and consumer product testing and life sciences testing combined. Counting under today’s owner means a group’s total includes deals made by companies it bought later.

The medians come from our TIC valuation research, 2,841 TIC deals since 2015, and use enterprise value (equity value plus net debt). Deal size is enterprise value where disclosed, otherwise the disclosed deal value. The size-band EBITDA medians count multiples between 1x and 60x, and two outlying revenue multiples are left out of the revenue median. Fewer deals publish EBITDA than revenue, so the two medians rest on different numbers of deals. The lab types on this page group our TIC subcategories. All figures are in US dollars.

Marcin Majewski

Founder and Managing Partner

As the founder of Aventis Advisors, Marcin has more than 20 years of experience in M&A and Corporate Finance. He specializes in the Technology sector with a particular focus on Software, IT Services as well as Business Services. During his career, he’s advised dozens of entrepreneurs and investors. Marcin is passionate about working with diverse people and learning the fascinating histories of founders. It’s all about connecting the world of business and finance, the creativity that goes into structuring deals (as each deal is unique), and developing meaningful connections between people worldwide.

We count 66 acquisitions by Tentamus or one of its companies since 2015. Fifty came from 2015 to 2021, including 15 in 2021, and 16 from 2022 to November 2026, with none in 2025.

Tentamus has been backed by the private equity firm BC Partners since 2021. The Munich private equity firm Auctus Capital Partners backed it from its founding in 2011. Christian Rebhan became chief executive in April 2024. Jochen Zoller became chairman and Abgar Barseyten a board member, both to focus on acquisitions (Tentamus release, 2 April 2024).

By its own figures, Tentamus has more than 90 locations in over 23 countries and 3,200 employees. Tentamus does not state its revenue. Outside Germany its labs sit in country groups in Iberia, Italy, North America and the UK, and in Greece, Cyprus, Bulgaria and Turkey under Veltia.

Eurofins Scientific, SGS, Normec, ALS and Mérieux NutriSciences have each made at least 20 deals since 2015 across food, agriculture and consumer product testing and life sciences testing, by our count. Three are listed, Normec is backed by private equity, and Mérieux NutriSciences is family-controlled and has made none of its deals in life sciences.

Tentamus, sellers and advisors have published no price for any of its 66 acquisitions. In our research TIC deals under $50M sold at a median 8.0x EBITDA (21 deals). Testing laboratory deals of every size sold at a median 10.1x (24 deals), on deals with a median size of about $60M. For a lab under $50M, the 8.0x is the closer guide.

Tentamus says on its website that each company it owns keeps its specialist expertise, local relationships and identity, and at least 13 labs kept their own name with “A Tentamus Company” added. Others took a Tentamus name. Five of the deal announcements we could read say the founder, the manager or the team stays, and labs in the same country have later been merged.

Tentamus buys small testing laboratories, mostly food, agricultural, pharmaceutical and medical device labs, and since 2022 almost only in countries where it has bought before. You can tell whether its offer is the best one only when the other laboratory groups and private equity platforms that want the lab bid at the same time. That is the process we run.

Yes. An offer from one buyer is priced without competition. We run a competitive sale process for you: we approach the laboratory groups, private equity platforms and other buyers with a real reason to want your lab, bring their offers to one deadline on the same information, and negotiate the price and terms through to closing, so you choose between the best offers, including the first. Talk to us before you reply to Tentamus or one of its companies.

Contact Us

Tell us about what you want to achieve; we can support you from start to close on your M&A journey.